Prognostication in young and old patients with Waldenström’s macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

We analyzed 232 patients with previously untreated, symptomatic WM, of whom 10% were 50 years of age and 21% were > 75 years of age. Disease features and response to treatment were similar among age groups. Patients > 75 years of age had significantly shorter survival (OS; 53 months vs. 113 months for those > 50-75 years vs. not reached for patients 50 years of age; P < .001). Despite the fact that 33% of elderly patients died of causes unrelated to WM, disease-specific survival (DSS) was 72 months for patients > 75 years, 120 months for those > 50-75 years and not reached for patients 50 years (P = .001). International Prognostic Scoring System for WM (IPSSWM) could discriminate 3 risk groups with significantly different OS or DSS. The addition of elevated serum lactate dehydrogenase in the IPSS improved the ability of IPSS to identify a group of patients with a significantly worse outcome (median survival, 55 months)

Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide

Purpose Alkylating agents and the anti-CD20 monoclonal antibody rituximab are among appropriate choices for the primary treatment of symptomatic patients with Waldenstrom macroglobulinemia ( WM), and they induce at least a partial response in 30% to 50% of patients. To improve these results, we designed a phase II study that included previously untreated symptomatic patients with WM who received a combination of dexamethasone, rituximab, and cyclophosphamide ( DRC). Patients and Methods Seventy-two patients were treated with dexamethasone 20 mg intravenously followed by rituximab 375 mg/ m(2) intravenously on day 1 and cyclophosphamide 100 mg/ m2 orally bid on days 1 to 5 ( total dose, 1,000 mg/ m2). This regimen was repeated every 21 days for 6 months. Patients’ median age was 69 years and many had features of advanced disease such as anemia ( 57%), hypoalbuminemia ( 40%), and elevated serum beta(2)-microglobulin ( 43%). Results On an intent-to-treat basis, 83% of patients ( 95% Cl, 73% to 91%) achieved a response, including 7% complete, 67% partial, and 9% minor responses. The median time to response was 4.1 months. The 2-year progression-free survival rate for all patients was 67%; for patients who responded to DRC, it was 80%. The 2-year disease-specific survival rate was 90%. Treatment with DRC was well tolerated, with 9% of patients experiencing grade 3 or 4 neutropenia and approximately 20% of patients experiencing some form of toxicity related to rituximab. Conclusion Our large, multicenter trial showed that the non -stem-cell toxic DRC regimen is an active, well-tolerated treatment for symptomatic patients with WM